Carbapenems: broad‑spectrum beta‑lactam antibiotics and clinical challenges

Structure and mechanism

The defining chemical feature of carbapenems is a beta‑lactam ring fused to a five‑membered ring with a carbon atom (hence the name). This configuration confers high affinity for penicillin‑binding proteins (PBPs), blocking synthesis of the bacterial cell wall and causing cell lysis. Their core structure also reduces susceptibility to many common beta‑lactamases produced by bacteria, which historically gave them an advantage over other beta‑lactam antibiotics. For more on bacteria targeted by these drugs, see relevant bacteria.

History and development

Carbapenems were developed from natural products produced by soil organisms; the prototype discovery traces back to metabolites of Streptomyces cattleya. Several clinically used agents were later developed, including imipenem, meropenem, ertapenem and doripenem, each differing in spectrum and dosing. Their introduction provided clinicians with reliable options for treating severe infections caused by organisms such as Escherichia coli and Klebsiella pneumoniae.

Clinical use and examples

• Indications: complicated intra‑abdominal infections, sepsis, severe hospital‑acquired pneumonia and resistant urinary tract infections when susceptible.
• Common members: imipenem, meropenem, ertapenem, doripenem.
• Administration: most are given intravenously; ertapenem has once‑daily dosing and a narrower spectrum.

Resistance, public‑health concerns and responses

Despite initial robustness, carbapenems are threatened by bacterial enzymes called carbapenemases that can hydrolyze these drugs. Notable carbapenemases include KPC, OXA‑48 types and metallo‑beta‑lactamases such as NDM (New Delhi metallo‑beta‑lactamase). NDM variants were first reported in bacteria originating from the Indian subcontinent and raised global concern when they appeared in many countries; see the original report context at NDM‑related findings. When carbapenem resistance occurs, treatment options narrow and clinicians may use older or more toxic drugs (for example colistin or tigecycline), combination regimens, or newer beta‑lactam/beta‑lactamase inhibitor combinations when active against the resistant enzyme. Infection prevention, antimicrobial stewardship and surveillance are central to limiting spread.

Notable distinctions and ongoing research

Carbapenems differ from other beta‑lactams by spectrum and chemical resilience to many enzymes, but they are not universally invulnerable. Research focuses on new inhibitors that restore activity against carbapenemase producers, alternative antimicrobials, and rapid diagnostics to guide therapy. Maintaining effective use of carbapenems involves careful laboratory testing, targeted prescribing and global coordination to slow the rise of resistance.